Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Radiosensitizing nucleosides

C J McGinn1, D S Shewach, T S Lawrence

  • 1Department of Radiation Oncology, University of Michigan, Ann Arbor 48109-0582, USA.

Journal of the National Cancer Institute
|September 4, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to Kibe Y et al. "Methodological concerns for investigating the effects of midtreatment break of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC)".

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2020
Same author

A mid-treatment break and reassessment maintains tumor control and reduces toxicity in patients with hepatocellular carcinoma treated with stereotactic body radiation therapy.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2019
Same author

Treatment data and technical process challenges for practical big data efforts in radiation oncology.

Medical physics·2018
Same author

Statistical controversies in clinical research: building the bridge to phase II-efficacy estimation in dose-expansion cohorts.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Characteristics of Successful and Probationary Football Officials.

The Physician and sportsmedicine·2016
Same author

Microphthalmia-associated transcription factor suppresses invasion by reducing intracellular GTP pools.

Oncogene·2016
Same journal

Response to Wang et al. and Shen et al.

Journal of the National Cancer Institute·2026
Same journal

Cluster randomized controlled trial of decision support for breast cancer chemoprevention, MiCHOICE.

Journal of the National Cancer Institute·2026
Same journal

Beyond R2: Assessing quality of trial level surrogate endpoints in colorectal cancer.

Journal of the National Cancer Institute·2026
Same journal

A novel classification of small bowel adenocarcinoma based on the hidden genome classifier: a multi-institutional study.

Journal of the National Cancer Institute·2026
Same journal

Response to Yu, Wang and Ge.

Journal of the National Cancer Institute·2026
Same journal

Re: Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphoma.

Journal of the National Cancer Institute·2026
See all related articles

Certain chemotherapy drugs enhance radiation therapy effectiveness by sensitizing tumor cells. Understanding these radiosensitizers, like fluoropyrimidines, can improve cancer treatment outcomes.

Area of Science:

  • Oncology
  • Pharmacology
  • Radiation Biology

Background:

  • Chemotherapeutic agents perturbing nucleotide metabolism can sensitize tumor cells to radiation, a process termed radiosensitization.
  • Fluoropyrimidines are clinically proven radiosensitizers, with thymidine analogues and hydroxyurea also showing efficacy.
  • Newer agents like gemcitabine and fludarabine show promise in combination with radiation therapy.

Purpose of the Study:

  • To review the mechanisms of radiosensitization induced by chemotherapeutic agents.
  • To explore the potential of novel agents and combination strategies in cancer treatment.
  • To understand the tumor selectivity of fluoropyrimidine-mediated radiosensitization.

Main Methods:

  • Review of existing clinical trials and laboratory investigations on radiosensitizers.

Related Experiment Videos

  • Analysis of biochemical pathways affected by chemotherapeutic drugs.
  • Integration of findings from cell cycle checkpoint control research.

    • Main Results:

    • Established clinical efficacy of fluoropyrimidines, thymidine analogues, and hydroxyurea as radiosensitizers.
    • Identification of gemcitabine and fludarabine as promising radiosensitizing agents.
    • Development of a hypothesis for fluoropyrimidine-mediated radiosensitization based on cell cycle control.

    Conclusions:

    • Rational manipulation of drug schedules and combination therapies can enhance radiosensitizer efficacy.
    • Further research into mechanisms and novel agents may improve cancer treatment outcomes.
    • Understanding radiosensitization is key to optimizing combined modality treatments.